Venrock Healthcare Capital Partners III L.P. 13D and 13G filings for Terns Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 5:51 pm Sale |
2024-09-30 | 13G | Terns Pharmaceuticals, Inc. TERN |
Venrock Healthcare Capital Partners III L.P. | 3,516,889 4.990% |
-980,228 (-21.80%) |
Filing |
| 2024-02-14 8:38 pm Purchase |
2023-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN |
Venrock Healthcare Capital Partners III L.P. | 4,497,117 7.300% |
789,226 (+21.29%) |
Filing |
| 2023-02-14 4:06 pm Purchase |
2022-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN |
Venrock Healthcare Capital Partners III L.P. | 3,707,891 7.700% |
641,650 (+20.93%) |
Filing |
| 2022-08-26 7:24 pm Purchase |
2022-08-16 | 13G | Terns Pharmaceuticals, Inc. TERN |
Venrock Healthcare Capital Partners III L.P. | 3,066,241 8.200% |
3,066,241 (New Position) |
Filing |